More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

Data ReadoutpositiveLeqembiPositive

AI Analysis

Summary

Eisai presented real-world LEADER study data showing that nearly 83% of early Alzheimer's disease patients treated with Leqembi (lecanemab) remained stable or improved over an average of 17 months. The data demonstrates sustained efficacy of the drug in clinical practice settings.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Nearly 83% of patients remained stable or improved; more than 75% remained stable and nearly 7% improved over average 17 months of treatment

Importance:7/10

Sentiment:

0.75

LecanemabAlzheimer's diseasereal-world evidenceLEADER studyAAIC 2026clinical data

Related Companies

$BIOA-B.ST $ESALY

Read the original article

Published by PR Newswire Pharma on July 14, 2026 3:39 PM

Read Original